Loading...

TRACON Pharmaceuticals

DB:T05
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
T05
DB
$20M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • TRACON Pharmaceuticals has significant price volatility in the past 3 months.
T05 Share Price and Events
7 Day Returns
-8.4%
DB:T05
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-73.3%
DB:T05
-7.4%
DE Biotechs
-5.6%
DE Market
T05 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TRACON Pharmaceuticals (T05) -8.4% -53.6% -27.6% -73.3% -90.9% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • T05 underperformed the Biotechs industry which returned -7.4% over the past year.
  • T05 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
T05
Industry
5yr Volatility vs Market
Related Companies

Value

 Is TRACON Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TRACON Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.589.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TRACON Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TRACON Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:T05 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.30
NasdaqGM:TCON Share Price ** NasdaqGM (2019-04-24) in USD $0.66
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TRACON Pharmaceuticals.

DB:T05 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TCON Share Price ÷ EPS (both in USD)

= 0.66 ÷ -1.30

-0.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TRACON Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TRACON Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TRACON Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:T05 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
50.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TRACON Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TRACON Pharmaceuticals's assets?
Raw Data
DB:T05 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.72
NasdaqGM:TCON Share Price * NasdaqGM (2019-04-24) in USD $0.66
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:T05 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TCON Share Price ÷ Book Value per Share (both in USD)

= 0.66 ÷ 0.72

0.91x

* Primary Listing of TRACON Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TRACON Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess TRACON Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TRACON Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TRACON Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TRACON Pharmaceuticals expected to grow at an attractive rate?
  • TRACON Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • TRACON Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • TRACON Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:T05 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:T05 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 50.9%
DB:T05 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 42%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:T05 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:T05 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 114 44 1
2022-12-31 95 34 1
2021-12-31 56 4 1
2020-12-31 61 -51 3
2019-12-31 9 -35 4
DB:T05 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -31 -35
2018-09-30 3 -25 -34
2018-06-30 10 -17 -24
2018-03-31 11 -12 -20
2017-12-31 9 -13 -19
2017-09-30 9 -17 -19
2017-06-30 3 -23 -26
2017-03-31 3 -28 -28
2016-12-31 3 -27 -27
2016-09-30 4 -29 -32
2016-06-30 5 -27 -32
2016-03-31 8 -21 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TRACON Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • TRACON Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:T05 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from TRACON Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T05 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.67 0.67 0.67 1.00
2022-12-31 0.52 0.52 0.52 1.00
2021-12-31 0.06 0.06 0.06 1.00
2020-12-31 -1.69 -1.25 -2.12 2.00
2019-12-31 -1.05 -0.93 -1.18 3.00
DB:T05 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.30
2018-09-30 -1.41
2018-06-30 -1.14
2018-03-31 -1.17
2017-12-31 -1.14
2017-09-30 -1.18
2017-06-30 -1.75
2017-03-31 -2.02
2016-12-31 -2.13
2016-09-30 -2.60
2016-06-30 -2.65
2016-03-31 -2.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TRACON Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TRACON Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TRACON Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TRACON Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TRACON Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TRACON Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TRACON Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TRACON Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TRACON Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TRACON Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T05 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.00 -34.96 7.28 6.57
2018-09-30 3.00 -33.76 7.21 6.54
2018-06-30 10.50 -23.51 6.95 6.37
2018-03-31 11.13 -20.32 7.40 6.49
2017-12-31 8.76 -19.10 7.61 6.72
2017-09-30 9.37 -18.86 7.80 6.81
2017-06-30 2.69 -25.90 7.84 6.58
2017-03-31 2.87 -27.63 7.81 6.51
2016-12-31 3.45 -27.01 7.86 6.32
2016-09-30 4.23 -31.74 7.61 6.38
2016-06-30 4.59 -32.32 7.26 6.44
2016-03-31 7.98 -26.94 6.69 5.92
2015-12-31 7.90 -24.44 5.69 5.25
2015-09-30 7.55 -16.04 4.75 4.41
2015-06-30 7.50 -11.58 3.79 3.74
2015-03-31 4.37 -9.71 2.71 3.18
2014-12-31 3.60 -7.11 2.13 2.80
2014-09-30 2.56 -6.74 1.78 2.43
2014-06-30 1.43 -7.36 1.62 2.31
2014-03-31 0.36 -7.85 1.55 2.18
2013-12-31 -7.96 1.48 2.09
2012-12-31 -5.14 1.45 1.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TRACON Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TRACON Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TRACON Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TRACON Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TRACON Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TRACON Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TRACON Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TRACON Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TRACON Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TRACON Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TRACON Pharmaceuticals Company Filings, last reported 3 months ago.

DB:T05 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.44 6.43 39.10
2018-09-30 28.56 6.34 47.17
2018-06-30 36.96 6.26 53.37
2018-03-31 42.49 7.07 62.49
2017-12-31 16.99 7.44 34.47
2017-09-30 21.82 7.32 35.86
2017-06-30 17.30 7.21 32.00
2017-03-31 22.99 7.09 36.72
2016-12-31 28.34 8.31 44.41
2016-09-30 17.78 8.32 35.11
2016-06-30 18.09 9.17 36.16
2016-03-31 25.32 9.00 45.49
2015-12-31 30.98 8.84 52.16
2015-09-30 41.06 6.92 57.66
2015-06-30 46.79 6.81 61.16
2015-03-31 49.17 7.79 65.29
2014-12-31 17.71 8.93 35.00
2014-09-30 20.39 9.46 39.21
2014-06-30 -3.66 7.19 13.57
2014-03-31 -2.73 2.45 10.36
2013-12-31 -1.42 2.44 2.28
2012-12-31 1.94 0.00 2.46
  • TRACON Pharmaceuticals's level of debt (30%) compared to net worth is satisfactory (less than 40%).
  • TRACON Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TRACON Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.
  • TRACON Pharmaceuticals has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -4% each year.
X
Financial health checks
We assess TRACON Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TRACON Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TRACON Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TRACON Pharmaceuticals dividends.
If you bought €2,000 of TRACON Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TRACON Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TRACON Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:T05 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:T05 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TRACON Pharmaceuticals has not reported any payouts.
  • Unable to verify if TRACON Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TRACON Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TRACON Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TRACON Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TRACON Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TRACON Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TRACON Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Charles Theuer
COMPENSATION $1,410,585
AGE 54
TENURE AS CEO 12.8 years
CEO Bio

Dr. Charles P. Theuer, M.D., Ph.D., has been Director at Oncternal Therapeutics, Inc. since March 2018. He has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since July 2006 and its Principal Financial Officer and Principal Accounting Officer since June 15, 2018. Dr. Theuer served as Vice President of Clinical Research and Chief Medical Officer of TargeGen Inc. from October 2004 to 2006, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer joined TargeGen from Pfizer where he led the clinical development of Sutent® (sunitinib maleate) in kidney cancer. He most recently served as Director of Clinical Oncology at Pfizer. Prior to that, he served as Director of Clinical Oncology of Idec Pharmaceuticals. Dr. Theuer also held senior positions at National Cancer Institute developing other agents, including small molecules and monoclonal antibody therapies. Dr. Theuer held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a Member of the Division of Surgical Oncology. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients and gastrointestinal cancer epidemiology. Dr. Theuer has been a Director of Tracon Pharmaceuticals, Inc. since July 2006. He completed a residency in general surgery at Harbor-UCLA Medical Center. Dr. Theuer holds a BS in Life Sciences from M.I.T., an M.D. from The University of California, San Francisco and a Ph.D. from The University of California, Irvine.

CEO Compensation
  • Charles's compensation has been consistent with company performance over the past year.
  • Charles's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the TRACON Pharmaceuticals management team in years:

0.9
Average Tenure
54
Average Age
  • The average tenure for the TRACON Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Charles Theuer

TITLE
CEO, President
COMPENSATION
$1M
AGE
54
TENURE
12.8 yrs

Scott Brown

TITLE
VP & Head of Finance
TENURE
0.3 yrs

Sharon Real

TITLE
Executive Vice President of Product Development
AGE
54
TENURE
4.8 yrs

Bonne Adams

TITLE
Executive Vice President of Clinical Operations
AGE
41
TENURE
4.8 yrs

Suzy Benedict

TITLE
Senior Vice President of Regulatory Affairs
TENURE
0.3 yrs

Jennifer Ellis

TITLE
Senior Vice President of Quality Assurance
TENURE
0.3 yrs

Mark Wiggins

TITLE
Chief Business Officer
AGE
62
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the TRACON Pharmaceuticals board of directors in years:

4.5
Average Tenure
60
Average Age
  • The tenure for the TRACON Pharmaceuticals board of directors is about average.
Board of Directors

Charles Theuer

TITLE
CEO, President
COMPENSATION
$1M
AGE
54
TENURE
12.8 yrs

Bill LaRue

TITLE
Director
COMPENSATION
$77K
AGE
67
TENURE
4.8 yrs

Paul Walker

TITLE
Director
COMPENSATION
$72K
AGE
43
TENURE
4.6 yrs

Martin Mattingly

TITLE
Director
COMPENSATION
$71K
AGE
61
TENURE
4.3 yrs

James Twiford

TITLE
Director
COMPENSATION
$62K
AGE
65
TENURE
10.6 yrs

Stan Gerson

TITLE
Member of the Scientific Advisory Board

William Kaelin

TITLE
Member of the Scientific Advisory Board
AGE
60

Steve Worland

TITLE
Director
COMPENSATION
$69K
AGE
60
TENURE
4.2 yrs

Jeff Hager

TITLE
Member of the Scientific Advisory Board
TENURE
2.3 yrs

Ted Wang

TITLE
Director
AGE
51
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Dec 18 Buy Charles Theuer Individual 21. Dec 18 21. Dec 18 49,000 €0.58 €28,233
03. Dec 18 Sell Puissance Capital Management LP Company 29. Nov 18 29. Nov 18 -4,326 €1.06 €-4,600
03. Dec 18 Buy Puissance Capital Management LP Company 29. Nov 18 29. Nov 18 4,326 €0.99 €4,296
X
Management checks
We assess TRACON Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TRACON Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Details
Name: TRACON Pharmaceuticals, Inc.
T05
Exchange: DB
Founded: 2004
$17,527,374
29,898,698
Website: http://www.traconpharma.com
Address: TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive,
Suite 800,
San Diego,
California, 92122,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TCON Common Stock Nasdaq Global Market US USD 30. Jan 2015
DB T05 Common Stock Deutsche Boerse AG DE EUR 30. Jan 2015
Number of employees
Current staff
Staff numbers
27
TRACON Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:54
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.